

Can milk proteins be a useful tool in the management of cardiometabolic health? An updated review of human intervention trials

Article

Accepted Version

Fekete, Á. A., Givens, D. I. ORCID: <https://orcid.org/0000-0002-6754-6935> and Lovegrove, J. A. ORCID: <https://orcid.org/0000-0001-7633-9455> (2016) Can milk proteins be a useful tool in the management of cardiometabolic health? An updated review of human intervention trials. *Proceedings of the Nutrition Society*, 75 (3). pp. 328-341. ISSN 1475-2719 doi: 10.1017/S0029665116000264 Available at <https://centaur.reading.ac.uk/64831/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.1017/S0029665116000264>

Publisher: Cambridge University Press

copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading

Reading's research outputs online

Can milk proteins be a useful tool in the management of cardiometabolic health? An updated review of human intervention trials

Ágnes A. Fekete^{1,2*}, D. Ian Givens² and Julie A. Lovegrove¹

¹Hugh Sinclair Unit of Human Nutrition and Institute for Cardiovascular and Metabolic Research (ICMR), Department of Food and Nutritional Sciences, Faculty of Life Sciences, University of Reading, Reading RG6 6AR, UK

²Food Production and Quality Research Division, School of Agriculture, Policy and Development, Faculty of Life Sciences, University of Reading, Reading RG6 6AR, UK

*Corresponding author: Ágnes A. Fekete, email: a.a.fekete@reading.ac.uk

Key words: dairy protein, metabolic health, blood pressure, vascular function

Running head: Milk proteins and cardiometabolic health

Abbreviation: ABPM: ambulatory blood pressure monitor; BP: blood pressure; CVD: cardiovascular diseases; DBP: diastolic blood pressure; FMD: flow mediated dilatation; LTP: lactotripeptides; RCT: randomised controlled trial; SBP: systolic blood pressure;

2 **Abstract:**

3 The prevalence of cardiometabolic diseases is a significant public health burden worldwide.
4 Emerging evidence supports the inverse association between greater dairy consumption and
5 reduced risk of cardiometabolic diseases. Dairy proteins may have an important role in the
6 favourable impact of dairy on human health such as blood pressure (BP) control, blood lipid
7 and glucose control. The purpose of this review is to update and critically evaluate the
8 evidence on the impacts of casein and whey protein in relation to metabolic function.
9 Evidence from acute clinical studies assessing postprandial responses to milk protein
10 ingestion suggests benefits on vascular function independent of BP, as well as improvement
11 in glycaemic homeostasis. Chronic interventions have been less conclusive, with some
12 showing benefits and others indicating a lack of improvement in vascular function. During
13 chronic consumption BP appears to be lowered and both dyslipidaemia and hyperglacemia
14 seems to be controlled. Limited number of trials investigated the effects of dairy proteins on
15 oxidative stress and inflammation. The beneficial changes in cardiometabolic homeostasis are
16 likely mediated through improvements in insulin resistance, however to gain more detailed
17 understanding on the underlying mechanism of milk proteins warrants further research. The
18 incorporation of meals enriched with dairy protein in the habitual diet may result in the
19 beneficial effects on cardiometabolic health. Nevertheless, future well-designed, controlled
20 studies are needed to investigate the relative effects of both casein and whey protein on BP,
21 vascular function, glucose homeostasis and inflammation.

23 Introduction

24 Milk and dairy products are widely consumed around the world on a daily basis. They are not
25 only an important source of nutrients in the human diet, but also represent important value in
26 the food chain providing opportunities for farmers, food processors, and retailers to contribute
27 to increased food security and poverty alleviation poverty⁽¹⁾. Therefore any change in milk
28 and dairy consumption will have multiple impacts on human and animal health, environment,
29 food security, and economics. Indeed, according to an OECD-FAO report, milk production is
30 projected to increase by 180 million tonnes in the next decade, predominantly in developing
31 countries⁽²⁾. Moreover, the inclusion of animal-derived products adds diversity to plant-based
32 diets, providing an important source of many essential nutrients, the dietary requirements of
33 which would be more difficult to meet by plant-based diets. However the potential health
34 impacts of animal-derived foods, and more specifically milk and dairy consumption, have
35 been questioned owing to their high saturated fat content, (for review, see:⁽³⁾). Yet, emerging
36 epidemiological evidence supports the beneficial effects of milk and dairy consumption on
37 health, particularly cardiometabolic health⁽⁴⁻⁶⁾.

38 Milk is a complex food, a unique package of many nutrients such as calcium, magnesium,
39 iodine, phosphorus, vitamin B₁₂, pantothenic acid, riboflavin, high quality protein, peptides,
40 and oligosaccharides. In the human body these bioactive components may interact with each
41 other and exert synergistic effects, making it difficult to assign the specific health effect of a
42 single component. Bovine milk, which is widely consumed around the world, contains
43 approximately 32-34 g/L protein of which 80% (w/w) is casein and 20% (w/w) is whey
44 protein. Both milk proteins consist of smaller protein fractions such as casein - alpha-s1,
45 alpha-s2, beta and kappa-casein, and whey - beta-lactoglobulin, alpha-lactalbumin,
46 lactoferrin, immunoglobulins, serum albumin, glycomacropeptide, enzymes and growth
47 factors. Milk proteins are considered to be high quality proteins. Whey protein is rich in
48 branched-chain amino acids (BCAA) such as leucine, isoleucine and valine, whilst casein
49 contains more histidine, methionine, phenylalanine, proline, serine, tyrosine and valine. It is
50 well established that casein and whey have differential effects on gastric emptying and
51 kinetics of digestion and absorption⁽⁷⁾. Intact micellar casein clots in the stomach due to the
52 low pH, and is, therefore, digested more slowly, which results in a prolonged and more
53 sustained AA release. In contrast, intact whey (which is acid soluble) or hydrolysed whey and
54 casein are absorbed more rapidly, with a slower AA release and half-life ⁽⁷⁾. It is, however, of
55 note that micellar casein is different from Ca or Na caseinate (micellar casein is acidified and

neutralised with alkali e.g. NaOH or Ca(OH)₂ in order to form caseinate), as the latter are soluble and thus may show similarities to whey in terms of digestion rates^(8, 9). As a result of their different inherent AA compositions leading to distinct absorption and kinetic behaviour, they may also have differential effects on human health.

The aim of this review is to update and critically evaluate the existing evidence on the effects of casein and whey on metabolic function, including blood pressure, vascular function, glucose and lipid metabolism, and inflammation.

Comprehensive literature search

A comprehensive literature search was conducted using the electronic databases MEDLINE, the Cochrane Library, EMBASE and Web of Science using the following terms: intervention, randomised controlled trials (RCT), clinical trials, high blood pressure, hypertension, anti-hypert*, vascular function, endothelial function, vascular stiffness, milk protein, milk peptide*, casein, hydrolysate, humans, lipids, insulin, glucose, inflammation. Furthermore, hand-searching was performed on the reference lists of both studies and review articles. In addition, Google and Google Scholar were used to confirm that the search was complete. The search period covered studies published until September 2015.

Blood pressure

Cardiovascular diseases (CVD) remain the leading cause of death in most countries worldwide. In the UK there has been a significant decrease in death rates since 1961, and due to a combination of better healthcare and preventative strategies, in 2012 CVD became the second main cause of death (CVD caused 28% of all death and cancer 29%)⁽¹⁰⁾. Approximately seven million people live with CVD in the UK which costs £19 billion each year (including premature death, lost productivity, hospital treatment, prescriptions) resulting in a significant economic burden⁽¹⁰⁾. Premature death from CVD can be prevented by improving modifiable risk factors. For example, it has been estimated that in the general population increasing physical activity, smoking cessation and dietary changes can lead to 50%, 20-30% and 15-40% mortality risk reduction, respectively⁽¹¹⁾.

High BP (hypertension) is the key modifiable risk factor of CVD and of stroke in particular. Nearly 30% of adults in the UK have high BP, however only half of them are aware of it and even less receive treatment⁽¹⁰⁾. High BP is present when systolic blood pressure (SBP) is ≥ 140 mmHg and/or diastolic blood pressure (DBP) is ≥ 90 mmHg⁽¹²⁾. It is important to treat hypertension and maintain BP in the normal range as elevated BP can cause irreversible damage to different organs such as kidneys, heart and eyes⁽¹²⁾.

Long-term studies on blood pressure

We have recently reviewed the evidence from RCTs on the antihypertensive effects of milk proteins and peptides⁽¹³⁾. For that review we systematically searched and reviewed the literature until December 2012. There was an imbalance in the literature as more RCTs were conducted using mainly one type of casein-derived peptides, called lactotripeptides (LTP). We, therefore conducted an updated meta-analysis on the impact of LTP on BP⁽¹⁴⁾, which included all available and relevant RCTs and detailed subgroup and regression analyses which were somewhat limited in previous meta-analyses in this area⁽¹⁵⁻¹⁸⁾. We found a small, but significant reduction in both SBP (-2.95 mmHg (95% CI: -4.17 , -1.73 ; $p < 0.001$)) and DBP (-1.51 mmHg (95% CI: -2.21 , -0.80 ; $p < 0.001$)) after four weeks of LTP supplementation in pre- and hypertensive populations. Since there was a statistically significant heterogeneity of treatment effects across studies, sub-group analyses were performed. These analyses suggested differences in countries where RCTs were conducted: Japanese studies reported significantly greater BP-lowering effect of LTP (-5.54 mmHg for SBP; and -3.01 mmHg for DBP), compared with European studies (-1.36 mmHg for SBP; and -0.83 mmHg for DBP; $p=0.002$ for SBP and <0.001 for DBP). This was confirmed in a recent meta-analysis which focused on Asian RCT only. However it only assessed SBP and the authors reported a very similar reduction of -5.63 mmHg in SBP as we found⁽¹⁹⁾. There may be several explanations for this observation. Firstly Japanese diets contains less milk and dairy products than European diets, therefore consumption of milk proteins may have a greater overall impact when compared to population that consume these proteins more regularly and in higher quantities⁽²⁰⁾. Furthermore there are reported ethnic differences in the response to drug administration, BP-lowering in particular⁽²¹⁾ which could impact on the response to these bioactive proteins and finally differences in response may have resulted from different spatial conformations (cis/trans) of LTP used in the studies, due to production

processes⁽²²⁾. Intriguingly, we also found a “small-study effect”, and when all bias was considered it shifted the treatment effect towards a less significant SBP and non-significant DBP reduction in response to LTP supplementation. We concluded that with potential bias considered, LTP consumption may still be effective in lowering blood pressure in mildly hypertensive or hypertensive groups⁽¹⁴⁾.

During our systematic literature search⁽¹³⁾ we found that there were very few studies investigating the BP-lowering effects of other casein-derived peptides in humans⁽²³⁻²⁷⁾. Furthermore these studies were limited, used different types of peptides and were often uncontrolled with poor methodological and study design. Due to these inconsistencies in study design, it was impossible to compare these data and no firm conclusion could be drawn on the antihypertensive effects of casein-derived peptides. Similarly, we found a limited number of RCTs conducted using intact whey or whey-derived peptides assessing their antihypertensive effects in humans⁽²⁸⁻³³⁾. These trials seem to be of higher quality than studies on casein-derived peptides, however the findings of these studies were also inconsistent⁽¹³⁾.

Since our review, published in 2013, three new studies which assessed the effects of milk proteins on BP as primary outcome were published. Petyaev *et al.*⁽³⁴⁾ examined the impacts of whey protein embedded in a protective lycopene matrix, a new proprietary formulation, so called whey protein lycosome, in a pilot study. Authors hypothesised that this formulation would protect whey protein from gastrointestinal degradation which would increase the bioavailability of the protein, and thus reduce the need for a high dose. They administered 70 mg of whey protein along with 7 mg of lycopene in the form of a capsule (WPL) and compared this to whey protein (70 mg) and lycopene (7 mg) separately (taken once a day for a month). A significant decrease in BP (-7 mmHg in SBP and -4 mmHg in DBP, $p < 0.05$) in the WPL group was reported compared to baseline only and no effect relative to the whey and lycopene given separately. Due to the nature of this pilot study, there was no information on blinding, the sample size was small (10/treatment group) and due to the limited statistical analysis further investigation is needed to evaluate the potential antihypertensive effect of WPL. Another RCT was conducted in overweight and obese adolescents (aged 12-15 years), who were asked to consume 1 litre/day of either water, skimmed milk, whey or casein (milk-based treatment drink contained 35 g/L protein) for 12 weeks⁽³⁵⁾. A decrease in brachial and central aortic DBP compared to baseline and control group (consuming water) was observed, whereas whey protein appeared to increase brachial and central aortic SBP, and central DBP.

The authors acknowledged several limitations of the study, including difficulties in recruitment, changes in the research protocol after study commencement and not controlling for the extra energy intake that 1 litre/day treatment drinks provided, which led to an increase in weight in those in the treatment groups compared to a loss in the control group which consumed water. Therefore due to these limitations it was difficult to draw firm conclusions from these data. A study of Figueroa *et al.* examined the effects of both whey and casein on BP and vascular function combined with exercise training in obese, hypertensive women⁽³⁶⁾. In their 4-week trial, participants were assigned to consume 30 g casein, whey or 34 g of maltodextrin (control) and perform resistance and endurance exercises 3 days/week under a qualified instructor's supervision. They reported significant reduction in both brachial and aortic SBP in both whey and casein groups compared to control, although this was not observed for DBP. The exercise training did not have additional effects on BP or arterial function, owing the beneficial effect on the cardiovascular system to the milk proteins (Table 1.).

In summary, emerging evidence suggest that milk protein consumption for at least four weeks may result in small blood pressure lowering, however further well controlled studies involving 24-hour ambulatory blood pressure monitor should be performed for confirmation.

Long-term studies on blood pressure

According to a typical Western eating pattern, people spend up to 18h/day in a postprandial state consuming three or more meals daily. Furthermore elevated postprandial lipemia, glycaemia and inflammation have been linked with increased risk for chronic disease development including diabetes and CVD⁽³⁷⁻³⁹⁾. Therefore dietary strategies that attenuate the postprandial metabolic disturbance are urgently required.

To date only two studies have evaluated the acute effects of milk proteins on BP. Pal and Ellis compared 45 g whey protein isolate, 45 g Na-caseinate with 45 g glucose in conjunction with a breakfast in normotensive overweight and obese women⁽³²⁾ but found no effect of treatment. A more recent study compared the postprandial effects of several dietary proteins (milk protein, pea protein and egg-white) and carbohydrate-rich meals on BP-related responses⁽⁴⁰⁾. Although the authors failed to specify the specific type of milk protein isolate used, its BP-lowering effect was not significantly different to pea protein, although both milk and pea

protein were significantly lower than egg-white ($p \leq 0.01$) (Table 1.). The lack of evidence on the acute BP effects of milk proteins warrants further research .

Vascular function

Vascular dysfunction is often used as an umbrella term for abnormalities of the vascular system, such as endothelial dysfunction and arterial stiffness⁽⁴¹⁾. The endothelium, the inner layer of cells of the vasculature, plays a key regulatory role in the vascular system. Any disturbance in endothelial function, such as increased permeability, reduced vasodilation and activation of thrombotic and inflammatory pathways, can lead to atherosclerotic development⁽⁴²⁾. Due to the central role of the endothelium in the development of atherosclerosis, several non-invasive methods have been developed to assess endothelial dysfunction. Nitric oxide plays a primary role in the control of vascular function and which is produced by the endothelium. Flow-mediated dilation (FMD) is considered to be the ‘gold standard’ method of assessing endothelial function and may surpass the predictive value of traditional risk factors such as smoking, elevated cholesterol level in predicting cardiovascular events in patients with established cardiovascular disease⁽⁴³⁾. However it is of note that this technique requires extensive training and is operator dependent, which may limit its value.

Arterial stiffness is a measure of arterial elasticity which is the ability to expand and contract along with cardiac pulsation and relaxation. CVD risk factors such as ageing, hypertension, smoking and diet have been shown to have a detrimental effect on arterial distensibility, inducing an imbalance between the synthesis and degradation of elastin and type 1 and 3 collagen⁽⁴⁴⁾. Pulse wave velocity (PWV) is considered to be the ‘gold-standard’ to measure arterial stiffness and has a substantial predictive value for CVD events⁽⁴⁵⁾.

Long-term studies on vascular function

Our previous review also evaluated the health effects of milk proteins and/or their peptides on vascular function⁽¹³⁾. In brief, we identified nine chronic RCTs^(33, 46-53), of which eight used lactotripeptides⁽⁴⁶⁻⁵⁴⁾ and one trial used intact casein and whey⁽³³⁾. These studies were diverse in several aspects of methodologies such as design, length and dose of treatment, subject characteristics and measures of vascular function, and most importantly type of milk proteins

used. Due to this heterogeneity, it is not possible to draw firm conclusions on the relative effects of milk proteins on the vascular function.

We have identified three further RCTs: Petyaev *et al.* examined the impacts of WPL not only on BP, but vascular reactivity, using FMD⁽³⁴⁾. They reported statistically significant improvements in FMD in the WPL group only (+2.6 %, $p < 0.05$) compared to baseline. Arnberg *et al.* also evaluated the effects of intact whey, casein and semi-skimmed milk on arterial stiffness using PWV, however failed to show any changes in vascular function⁽³⁵⁾. However Figueroa and colleagues reported favourable changes in augmentation index (AI: a measure of arterial stiffness) and brachial-PWV in both whey and casein groups combined with exercise, compared to the control group. It is of note that the randomisation may not have been adequate as the baseline values for both BP and arterial stiffness were different than the whey and casein groups which may have confounded the study (Table 2.).

Short-term studies on vascular function

Only four RCTs were conducted to evaluate the effects of milk proteins on vascular function in a postprandial setting^(32, 54-56). Pal and Ellis failed to show any acute effects of whey and casein ingestion with a meal in normotensive obese postmenopausal women on arterial stiffness measured by pulse wave analysis⁽³²⁾. Likewise, Turpeinen *et al.* also did not observe any statistically significant change in arterial stiffness measured by PWV after acute ingestion of 25 mg lactotripeptides with 2 g plant sterol ester mixed in a milk drink in mildly hypertensive subjects⁽⁵⁴⁾. However Ballard and colleagues reported significant improvements in arterial reactivity assessed by FMD (+4.3 %) at 120 min after ingestion compared with placebo corresponding time point, ($p < 0.05$) in mildly hypertensive, overweight individuals after whey hydrolysate (5 g NOP-47) ingestion with water⁽⁵⁵⁾. Mariotti *et al.* failed to report any significant effects of casein, whey or α -lactalbumin enriched whey protein on digital volume pulse (a measure of arterial stiffness)⁽⁵⁷⁾ (Table 2.).

Intriguingly, BP-lowering effects of milk proteins were not associated with changes in vascular function in the reviewed RCTs⁽¹³⁾ which is confirmed by emerging evidence on the relationship between BP and arterial stiffness. This suggests that the interaction between BP and arterial stiffness may be bi-directional^(58, 59) via complex interactions between different pathways such as inflammatory^(60, 61), hormonal (e.g. leptin, insulin)⁽⁶¹⁻⁶³⁾ and disturbance in

endothelial-derived mediators⁽⁵⁸⁾. Therefore it is important to determine the effect on other mediators of risk that may indirectly affect BP.

Glycaemic control

Insulin has a range of biological actions within the human body⁽⁶⁴⁾, not only has it a key regulatory role in metabolic energy disposal and storage in tissues, but it is responsible for cell growth and development⁽⁶⁵⁾, ion transport⁽⁶⁶⁾, and sympathetic nervous system activity⁽⁶⁷⁾. In addition, insulin has haemodynamic activities such as increasing blood flow and cardiac output, probably via increased NO production⁽⁶⁴⁾. Giugliano *et al.* demonstrated insulin release after an intravenous infusion of L-arginine resulted in improvements in FMD⁽⁶⁸⁾. However Gates *et al.* showed an insulin-independent vasodilation after L-arginine administration⁽⁶⁹⁾. Similarly, Ballard and colleagues reported an insulin-independent FMD improvement in response to the acute ingestion of a whey-derived peptide, NOP-47⁽⁵⁵⁾.

It is well established that food proteins and more specifically AAs acutely stimulate insulin secretion⁽⁷⁰⁾ with several AAs possessing direct insulintropic effects^(71, 72). Both whey and casein appear to increase insulin secretion, however to different extents⁽⁷³⁾. This may be due to their effect on gastric emptying, absorption and kinetics, since the insulin responses seemed to correlate with the increase in plasma AA concentration after protein ingestion⁽⁷⁴⁾. Likewise, hydrolysates appear to increase insulin production more than intact proteins⁽⁷⁵⁾.

It is not yet known how milk proteins exert their beneficial effects on glucose homeostasis, however, BCAAs, in particular, leucine, isoleucine, valine, lysine and threonine are shown to act as insulin secretagogues (inducing insulin secretion from pancreatic β -cells), with leucine reportedly having the greatest insulintropic effect acutely⁽⁷⁶⁾. This may be via the regulation of both ATP production (by metabolic oxidation and allosteric activation of glutamate dehydrogenase) and K_{ATP} activity⁽⁷⁷⁾. Similarly, BCAA and particularly leucine, has been reported to activate the mammalian rapamycin (mTOR) pathway resulting in a higher incretin hormone (insulin, glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP)) synthesis^(77, 78). GIP is also known as glucose-dependent insulintropic peptide, synthesised by K cells found in the mucosa of the duodenum and jejunum in response to food ingestion, which may subsequently further induce insulin production⁽⁷⁹⁾. While the effect of GIP appears to be more pronounced at normoglycaemic levels, GLP-1 is more active during

hyperglycaemia⁽⁷⁹⁾. Jakubowitz and Froy showed that whey protein drink increased GIP response (+80%) in healthy adults, yet a mixture of BBCA mimicking the supply of AA in whey protein, failed to exert the same effect⁽⁸⁰⁾. Therefore they suggested that certain bioactive peptides and/or AAs deriving from whey protein during digestion may be responsible for this action⁽⁸⁰⁾. GLP-1 is a potent antihyperglycemic hormone secreted by intestinal L cells⁽⁷⁹⁾. Interestingly, it has been shown to possess cardioprotective effects, which may be further complemented by natriuretic and antioxidative stress on the kidneys leading to beneficial impacts on BP and vasculature⁽⁸¹⁾. This warrants further consideration in future research when the effects of milk proteins are assessed on the cardiovascular system. Additionally, GLP-1 was more pronounced in healthy subjects after whey consumption compared to casein or soya, however after 2 hours of ingestion the concentration of the hormone decreased, while it continued to increase after casein^(80, 82, 83). This may be explained by the different plasma kinetics of milk proteins. Two enzyme inhibitory peptides deriving from milk proteins have been associated with the beneficial effects on the glucose homeostasis: dipeptidyl peptidase-IV (DPP-IV) enzyme inhibitors and alpha-glucosidase (AG) enzyme inhibitors. Although DPP-IV plays several roles in different physiological processes, it has a distinct effect on glucose homeostasis by degrading incretin hormones: GLP-1 and GIP⁽⁸⁴⁾. Whereas there is a definite lack of human studies examining the effects of DPP-IV inhibitory peptides deriving from milk proteins; some *in silico* (computer-aided), *in vitro* and limited animal studies suggesting a potential role in controlling glucose metabolism. Lacroix and Li-Chan proposed that casein appears to be a better source of DPP-IV inhibitory peptides than whey protein⁽⁸⁵⁾. However, *in vitro* and *in vivo* studies suggest that whey protein may be equal or a better source of these inhibitory peptides (for review see⁽⁸⁶⁾). The AG enzyme is found in the brush border of the enterocytes in the small intestine and is responsible for the synthesis and breakdown of carbohydrate by cleaving glycosidic bonds in complex carbohydrates to produce monosaccharides. A potential therapy in type 2 diabetic patients could be to reduce the absorption of glucose by carbohydrate hydrolysing enzymes such as AG, which may also enhance and promote GLP-1 secretion⁽⁸⁷⁾. A very limited number of *in vitro* studies demonstrated that AG inhibitory peptides may be derived from whey protein^(88, 89). This clearly warrants further research.

Short-term studies on glycaemic control

305

306 Milk proteins have been extensively investigated for their insulinotropic and glucose-lowering
307 effects in healthy subjects^(73, 75, 82, 83, 90-99) and to a limited extent in individuals with
308 suboptimal glucose control⁽¹⁰⁰⁻¹⁰⁶⁾. The dose varied significantly between studies from as little
309 as 10 g^(92, 105, 106) to 51 g⁽⁹¹⁾. Milk proteins were administered on their own or with a meal or
310 even served as pre-meals. Current evidence on the effects of whey protein on glucose control
311 appears to be more promising than casein, furthermore it has been proposed that whey protein
312 may be as effective at inducing insulin secretion as medication (sulfonylureas) prescribed for
313 management of hyperglycaemia in type 2 diabetic patients^(80, 107) (Table 3.). Thus providing a
314 rationale for individuals with impaired glucose control or for patients with T2DM (type 2
315 diabetes mellitus) to consume whey protein prior to or with meals to control postprandial
316 glucose metabolism. Future studies should examine the minimum dose at which whey protein
317 exerts beneficial effects. Similarly due to the different timeframe by which milk proteins have
318 an effect, longer postprandial trials (e.g. 24h) may provide important information on how
319 casein could improve hyperglycaemia in individuals characterised by insulin resistance but
320 with functional β -cells.

321

322 ***Long-term studies on glycaemic control***

323 To best of our knowledge, only three studies have investigated the chronic supplementation of
324 milk proteins, rather than milk or dairy products, on glycaemic control. Pal *et al.* examined
325 the effects of whey and casein (2 x 27g/day for 12 weeks) in overweight and obese
326 subjects⁽⁹⁶⁾. Most subjects had borderline impaired glucose tolerance at baseline, but at the
327 end of the intervention a reduced fasting insulin concentration was observed in the whey
328 protein group compared with the control group (glucose), although no change in fasting
329 glucose was reported. In another study, a whey fermentation product (malleable protein
330 matrix, MPM) decreased fasting plasma glucose concentration after three months
331 supplementation compared to the control group, which was more pronounced in individuals
332 with impaired fasting glucose at baseline⁽¹⁰⁸⁾. An acute-in-chronic study also reported a
333 decrease in postprandial glucose response in whey group, which remained unchanged after the
334 four-week supplementation period⁽¹⁰²⁾ (Table 3.).

335

Lipid metabolism

Short-term studies on lipids

Postprandial triacylglycerolaemia has been associated with markers of early atherosclerosis such as endothelial dysfunction and carotid media thickness^(109, 110) and is strongly influenced by the composition of a meal: including the quality and quantity of fat^(111, 112) and carbohydrate^(113, 114). In theory due to the insulinogenic effects of milk proteins, their consumption would be predicted to attenuate postprandial lipaemia, as insulin has an inhibitory effect on hormone-sensitive lipase and hepatic release of free fatty acid (FFA) and stimulatory effect on lipoprotein lipase which hydrolyses triacylglycerol for metabolism or storage. However evidence from postprandial RCT is limited. Postprandial investigations reported decrease in triacylglycerols (TAG) after both whey and casein ingestion in combination with a fat-rich meal in obese⁽⁹⁸⁾ and individuals with T2DM^(103, 115), but showed no effect on TAG after acute consumption of whey protein^(99, 104). Free fatty acid also decreased after whey and casein ingestion in obese⁽⁹⁹⁾ and T2DM patients⁽¹⁰⁴⁾. It is of note that parameters of lipid metabolism such as low- and high-density lipoproteins and total cholesterol remain stable acutely^(116, 117).

Recently an acute study reported that casein with a high fat, high energy meal, compared to whey protein and α -lactalbumin enriched whey protein, significantly reduced postprandial TAG and had a marked effect of chylomicron kinetics⁽⁵⁷⁾. This could be due to the different physicochemical makeup of casein and whey protein, as casein forms a gel in the stomach influencing the rate of absorption and gastric emptying (Table 4.).

Long-term studies on lipids

To date, five chronic RCT, which examined the lipid lowering effects of milk proteins, have been identified. Three month supplementation of whey (2 x 25 g/day) and casein (2 x 25 g/day) during an ad libitum weight regain diet after substantial diet-induced weight loss in healthy obese subjects resulted in no change in plasma lipids⁽¹¹⁸⁾. However whey protein isolate (2 x 27 g/day) significantly reduced fasting TAG, total cholesterol and LDL-cholesterol after three months in overweight, obese individuals⁽⁹⁶⁾. Another three month supplementation study with MPM (15 g/day protein in two daily servings of 150g yoghurt) reduced fasting TAG, which was more pronounced in subjects with elevated baseline

TAG⁽¹⁰⁸⁾. In a six week study casein (35 g/day) also reduced total cholesterol in hypercholesterolemic subjects⁽¹¹⁹⁾. Petyaev *et al.* reported a decrease in LDL-cholesterol, TAG and TC in their pilot study⁽³⁴⁾ (Table 4.). The limited evidence suggests that milk proteins have a beneficial impact on fasted lipids, although further studies are required. However it is not clear as to possible mechanisms of action although insulin may play a role. *In vitro* studies suggest that milk proteins and BCAA inhibit expression of genes involved in intestinal fatty acid and cholesterol absorption and synthesis⁽¹²⁰⁾. Whey has been shown to induce urinary excretion of tricarboxylic acid cycle (TCA) compounds such as citric acid and succinic acid in rats, which are substrates for lipogenesis, suggesting an increased catabolic state (e.g. lipolysis) and reduced lipid accretion compared to casein⁽¹²¹⁾. This could be a possible mechanism of lipid reduction. Similarly, in another metabolic study conducted in humans, cheese (casein) appeared to induce lowering of urinary citrate⁽¹²²⁾, which suggests that cheese consumption affects the TCA cycle. Additionally, microbiota-related metabolite, hippuric acid was significantly higher in the cheese group, than in the milk, implying a stimulation of gut bacteria activity. The enhanced bacterial activity also resulted in higher short-chain fatty acids (SCFA)⁽¹²²⁾, which have been proposed as key regulatory metabolites in lipid metabolism⁽¹²³⁾. This effect may be due to the cheese matrix rather than the casein per se. An *in vivo* study proposed another potential mechanism of action through decreased lipid infiltration into the liver in rats with non-alcoholic fatty liver⁽¹²⁴⁾. Another possible putative mechanism is increased fat oxidation. Lorenzen *et al.* demonstrated an increased lipid oxidation after acute casein consumption compared to whey⁽¹²⁵⁾. They speculated that it may be due to lower insulin secretion after casein consumption relative to whey since insulin downregulates lipid oxidation. However insulin was not measured in the study and this mechanism could not be confirmed. The same research group examined the effects of dairy Ca on lipid metabolism in conjunction with a low and high fat diet during 10 days⁽¹²⁶⁾. They found that dairy Ca attenuates the increase in total and LDL-cholesterol, without affecting the rise in HDL-cholesterol. This observed phenomenon may be due to the formation of insoluble Ca-fatty acid soaps and/or the production of hydrophobe aggregation with bile and with other fatty acids⁽¹²⁶⁻¹²⁸⁾.

Inflammation and oxidative stress

Inflammation and oxidative stress are chronic conditions which contribute to many diseases such as obesity⁽¹²⁹⁾, T2DM⁽¹³⁰⁾ and CVD⁽¹³¹⁾. Different dietary components have an impact on low-grade inflammation⁽¹³²⁾, however there is a lack of RCTs evaluating the acute and chronic consumption of milk proteins on inflammation or oxidative stress with inconsistent outcomes.

Long-term studies on inflammation and oxidative stress

A recent meta-analysis evaluated the effects of chronic consumption of whey protein and hydrolysate on C-reactive protein (CRP), a systemic inflammatory marker⁽¹³³⁾. Nine RCTs were included which showed a small, non-significant reduction in CRP 0.42mg/L (95% CI -0.96, 0.13). Sub-group analyses suggested that >20 g/day may be more effective, and elevated baseline CRP level (≥ 3 mg/L) could be more responsive to whey or whey peptides consumption⁽¹³³⁾. Similarly, Arnberg *et al.* reported no change in CRP in adolescence after whey, casein or skim milk consumption for 12 weeks⁽³⁵⁾.

Interleukin (IL)-6, IL-8 and tumour necrosis factor (TNF)- α are also recognised inflammatory markers, which induce CRP. Pal and Ellis failed to observe significant changes in these inflammatory markers (2 x 27g whey or casein or glucose for 12 weeks) in overweight individuals⁽³³⁾. However Sugawara *et al.* reported decreased level of IL-6, IL-8 and TNF- α in patients with chronic obstructive pulmonary disease after whey intervention compared with control group⁽¹³⁴⁾. Likewise, IL-6 and TNF- α were decreased after lactoferrin consumption for six months in postmenopausal women⁽¹³⁵⁾. Similarly Hirota *et al.* reported decreased levels of TNF- α in mildly hypertensive subjects fed with the casein-derived lactotripeptides⁽⁴⁶⁾ (Table 5.).

Long-term studies on inflammation and oxidative stress

Pal and Ellis, also reported no change in IL-6, IL-8 and TNF- α in a postprandial study investigating whey and casein⁽³²⁾. Likewise, a whey-derived peptide, NOP-47, also failed to change the level of serum cytokines (TNF- α , IL-6, IL-8, monocyte chemoattractant protein-1, vascular endothelial growth factor, soluble E-selectin, soluble vascular cell adhesion molecule-1) and chemokines⁽⁵⁶⁾. However consumption of a cake containing whey protein after exhaustive cycling in nine subjects reported reduced levels of CRP and IL-6 by 46% and 50%, respectively⁽¹³⁶⁾. Holmer-Jensen *et al.* assessed the postprandial effects of whey protein, casein, gluten and cod on low-grade inflammatory markers (monocyte chemotactic protein-1 (MCP-1), CC chemokine ligand-5 (CCL5/RANTES)) in conjunction with a high fat meal⁽¹³⁷⁾.

They reported that all meals increased CCL/RANTES, however the smallest increase was observed after the whey protein meal. MCP-1 was initially suppressed after all meals, and the meal containing whey protein induced the smallest overall postprandial suppression⁽¹³⁷⁾ (Table 5.).

The mechanism of action of milk proteins on oxidative stress and inflammation are unclear but Ca may suppresses the pro-inflammatory and reactive oxygen species production *in vitro*⁽¹³⁸⁾. Interestingly, the milk protein-derived inhibitors of the angiotensin-I-converting enzyme may also be involved in the anti-inflammatory process⁽¹³⁹⁾.

Conclusion and implication for future studies

Taken together, there is a growing number of RCTs which suggest that casein and whey protein may have a role in cardiometabolic health. Studies focussed on reducing chronic disease risk factors such as hypertension and dysregulated lipid/glucose metabolism by non-pharmacological, dietary strategies will have significant implications not only for social and economic welfare, but for the healthcare system.

Due to the different physicochemical makeup of casein and whey protein, they may exert differential effects *in vivo* in humans. Notably, manufacturing may play a significant role in the physiological effects of milk proteins, however future studies should investigate which processing method results in more bioactive effects. There is inconclusive evidence on the relative impacts of milk proteins on diurnal BP and vascular function, yet there appears to be strong evidence on the insulinotropic impacts of dairy proteins, owing to the specific AA composition such as BCAA. They also appear to play a beneficial role in lipid homeostasis (Table 1.). Nevertheless the mechanism underlying the action of dairy proteins on the cardiometabolic health warrants further research.

The incorporation of a meal enriched with protein in the habitual diet may result in the improvement of cardiometabolic health as well as the prevention of developing cardiometabolic diseases. Additionally, in contrast with pharmacological antihypertensive treatments, food-derived proteins have not been shown to cause any side-effects or hypotension, making them safe to consume by individuals with a variety of other disease conditions. After careful consideration of the available evidence and knowledge gaps, we have conducted two double-blind, controlled, cross-over studies aiming to compare the

chronic (n=38) and postprandial (n=27) impacts of whey protein isolate (2 x 28 g) and Ca-caseinate (2 x 28 g) with control (2 x 26 g, maltodextrin) on vascular function, BP, markers of insulin resistance, lipid metabolism and inflammatory status in men and women with mild hypertension ($\geq 120/80$ mmHg). These studies aim to provide valuable information on the relative effects of milk proteins on blood pressure and on detailed aspects of vascular function compared with maltodextrin. These trials will further our knowledge of whether milk proteins have significant influences as health-promoting food components and whether the public as well as the food industry could benefit from it. The results from these studies are likely to be available in mid-2016.

Financial support

This review received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. AAF is supported by a UK Biotechnology and Biological Sciences Research Council (BBSRC) studentship. The human trials were financially supported by BBSRC and Volac Int. Ltd.

Declaration of interest

JAL and DIG have previously received funding for research from AHDB Dairy. JAL and DIG have acted as an advisor to the Dairy Council. JAL and DIG have received 'in kind' foods from Arla for an MRC funded study.

Authorship

AAF conceived and wrote the manuscript. All authors critically reviewed and approved the final version of the manuscript

485 **References:**

- 486 1. Muehlhoff E BA, McMahon D. (2013) Milk and dairy products in human nutrition:
 487 Food and Agricultural Organization of the United Nations.
 488 <http://www.fao.org/docrep/018/i3396e/i3396e.pdf> (Accessed August 2015).
- 489 2. OECD-FAO Agricultural Outlook 2014-2023 (2014). OECD Publishing.
 490 [https://www.embrapa.br/documents/1024963/1025740/OECD-](https://www.embrapa.br/documents/1024963/1025740/OECD-FAO_Agricultural_Outlook_2014-2023/20082926-0f88-4159-970a-2a1c65795c47)
 491 [FAO_Agricultural_Outlook_2014-2023/20082926-0f88-4159-970a-2a1c65795c47](https://www.embrapa.br/documents/1024963/1025740/OECD-FAO_Agricultural_Outlook_2014-2023/20082926-0f88-4159-970a-2a1c65795c47)
 492 (Accessed August 2015).
- 493 3. Markey O, Vasilopoulou D, Givens DI, *et al.* (2014) Dairy and cardiovascular health:
 494 Friend or foe? *Nutr Bull.* **39**(2):161-71.
- 495 4. Elwood PC, Pickering JE, Givens DI, *et al.* (2010) The consumption of milk and dairy
 496 foods and the incidence of vascular disease and diabetes: an overview of the evidence.
 497 *Lipids.* **45**(10):925-39.
- 498 5. Ralston RA, Lee JH, Truby H, *et al.* (2012) A systematic review and meta-analysis of
 499 elevated blood pressure and consumption of dairy foods. *J Hum Hypertens.* **26**(1):3-
 500 13.
- 501 6. Aune D, Norat T, Romundstad P, *et al.* (2013) Dairy products and the risk of type 2
 502 diabetes: a systematic review and dose-response meta-analysis of cohort studies. *Am J*
 503 *Clin Nutr.* **98**(4):1066-83.
- 504 7. Boirie Y, Dangin M, Gachon P, *et al.* (1997) Slow and fast dietary proteins differently
 505 modulate postprandial protein accretion. *Proc Natl Acad Sci USA.* **94**(26):14930-5.
- 506 8. Phillips SM. (2011) A comparison of whey to caseinate. *Am J Physiol Endocrinol*
 507 *Metab.* **300**(3):E610; author reply E1-2.
- 508 9. Reitelseder S, Agergaard J, Doessing S, *et al.* (2011) Whey and casein labeled with L-
 509 [1-13C]leucine and muscle protein synthesis: effect of resistance exercise and protein
 510 ingestion. *Am J Physiol Endocrinol Metab.* **300**(1):E231-42.
- 511 10. Townsend N WJ, Bhatnagar P, Wickramasinghe K, *et al.* (2014) Cardiovascular
 512 disease statistics. British Heart Foundation: London. 2014.
- 513 11. Iestra JA, Kromhout D, van der Schouw YT, *et al.* (2005) Effect size estimates of
 514 lifestyle and dietary changes on all-cause mortality in coronary artery disease patients:
 515 a systematic review. *Circulation.* **112**(6):924-34.
- 516 12. Mancia G, De Backer G, Dominiczak A, *et al.* (2007) Guidelines for the management
 517 of arterial hypertension: The Task Force for the Management of Arterial Hypertension

of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J.* **28**(12):1462-536.

13. Fekete AA, Givens DI, Lovegrove JA. (2013) The impact of milk proteins and peptides on blood pressure and vascular function: a review of evidence from human intervention studies. *Nutr Res Rev.* **26**(2):177-90.
14. Fekete AA, Givens DI, Lovegrove JA. (2015) Casein-derived lactotripeptides reduce systolic and diastolic blood pressure in a meta-analysis of randomised clinical trials. *Nutrients.* **7**(1):659-81.
15. Xu JY, Qin LQ, Wang PY, *et al.* (2008) Effect of milk tripeptides on blood pressure: a meta-analysis of randomized controlled trials. *Nutrition.* **24**(10):933-40.
16. Cicero AF, Gerocarni B, Laghi L, *et al.* (2011) Blood pressure lowering effect of lactotripeptides assumed as functional foods: a meta-analysis of current available clinical trials. *J Hum Hypertens.* **25**(7):425-36.
17. Turpeinen AM, Jarvenpaa S, Kautiainen H, *et al.* (2013) Antihypertensive effects of bioactive tripeptides-a random effects meta-analysis. *Ann Med.* **45**(1):51-6.
18. Qin LQ, Xu JY, Dong JY, *et al.* (2013) Lactotripeptides intake and blood pressure management: a meta-analysis of randomised controlled clinical trials. *Nutr Metab Cardiovasc Dis.* **23**(5):395-402.
19. Chanson-Rolle A, Aubin F, Braesco V, *et al.* (2015) Influence of the Lactotripeptides Isoleucine-Proline-Proline and Valine-Proline-Proline on Systolic Blood Pressure in Japanese Subjects: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *PLoS One.* **10**(11):e0142235.
20. Bulletin of the International Dairy Federation (2010) The World Dairy Situation 2010. http://www.milksa.co.za/sites/default/files/KORINL070_world_dairy_situation_2010.pdf.
21. Johnson JA. (2008) Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. *Circulation.* **118**(13):1383-93.
22. Siltari A, Viitanen R, Kukkurainen S, *et al.* (2014) Does the cis/trans configuration of peptide bonds in bioactive tripeptides play a role in ACE-1 enzyme inhibition? *Biologics.* **8**:59-65.
23. Ashar MC, R. (2004) Fermented milk containing ACE-inhibitory peptides reduces blood pressure in middle aged hypertensive subjects. *Milchwissenschaft.* **59**:363-6.

24. Sekiya S KY, Kita E, Imamura Y, *et al.* (1992) Antihypertensive effects of tryptic hydrolysate of casein on normotensive and hypertensive volunteers. *J Nutr Food Sci.* **45**:513–7.
25. Townsend RR, McFadden CB, Ford V, *et al.* (2004) A randomized, double-blind, placebo-controlled trial of casein protein hydrolysate (C12 peptide) in human essential hypertension. *Am J Hypertens.* **17**(11 Pt 1):1056-8.
26. Cadee JA, Chang CY, Chen CW, *et al.* (2007) Bovine casein hydrolysate (c12 Peptide) reduces blood pressure in prehypertensive subjects. *Am J Hypertens.* **20**(1):1-5.
27. Sugai R. (1998) ACE inhibitors and functional foods. *Bull IDF.* **336**(17-20).
28. Kawase M, Hashimoto H, Hosoda M, *et al.* (2000) Effect of administration of fermented milk containing whey protein concentrate to rats and healthy men on serum lipids and blood pressure. *J Dairy Sci.* **83**(2):255-63.
29. Lee YM, Skurk T, Hennig M, *et al.* (2007) Effect of a milk drink supplemented with whey peptides on blood pressure in patients with mild hypertension. *Eur J Nutr.* **46**(1):21-7.
30. Fluegel SM, Shultz TD, Powers JR, *et al.* (2010) Whey beverages decrease blood pressure in prehypertensive and hypertensive young men and women. *Int Dairy J.* **20**(11):753-60.
31. Hodgson JM, Zhu K, Lewis JR, *et al.* (2012) Long-term effects of a protein-enriched diet on blood pressure in older women. *Br J Nutr.* **107**(11):1664-72.
32. Pal S, Ellis V. (2011) Acute effects of whey protein isolate on blood pressure, vascular function and inflammatory markers in overweight postmenopausal women. *Br J Nutr.* **105**(10):1512-9.
33. Pal S, Ellis V. (2010) The chronic effects of whey proteins on blood pressure, vascular function, and inflammatory markers in overweight individuals. *Obesity* (Silver Spring). **18**(7):1354-9.
34. Petyaev IM, Dovgalevsky PY, Klochkov VA, *et al.* (2012) Whey protein lysosome formulation improves vascular functions and plasma lipids with reduction of markers of inflammation and oxidative stress in prehypertension. *ScientificWorldJournal.* **2012**:269476.
35. Arnberg K, Larnkjaer A, Michaelsen KF, *et al.* (2013) Casein improves brachial and central aortic diastolic blood pressure in overweight adolescents: a randomised, controlled trial. *J Nutr Sci.* **2**:e43.

36. Figueroa A, Wong A, Kinsey A, *et al.* (2014) Effects of milk proteins and combined exercise training on aortic hemodynamics and arterial stiffness in young obese women with high blood pressure. *Am J Hypertens.* **27**(3):338-44.
37. Alipour A, Elte JW, van Zaanen HC, *et al.* (2007) Postprandial inflammation and endothelial dysfunction. *Biochem Soc Trans.* **35**(Pt 3):466-9.
38. Klop B, Proctor SD, Mamo JC, *et al.* (2012) Understanding postprandial inflammation and its relationship to lifestyle behaviour and metabolic diseases. *Int J Vasc Med.* **2012**:947417.
39. Lopez-Miranda J, Williams C, Lairon D. (2007) Dietary, physiological, genetic and pathological influences on postprandial lipid metabolism. *Br J Nutr.* **98**(3):458-73.
40. Teunissen-Beekman KF, Dopheide J, Geleijnse JM, *et al.* (2014) Differential effects of proteins and carbohydrates on postprandial blood pressure-related responses. *Br J Nutr.* **112**(4):600-8.
41. Schachinger V, Britten MB, Zeiher AM. (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. *Circulation.* **101**(16):1899-906.
42. Verma S, Anderson TJ. (2002) Fundamentals of endothelial function for the clinical cardiologist. *Circulation.* **105**(5):546-9.
43. Thijssen DH, Black MA, Pyke KE, *et al.* (2011) Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. *Am J Physiol Heart Circ Physiol.* **300**(1):H2-12.
44. Bruno RM, Bianchini E, Faita F, *et al.* (2014) Intima media thickness, pulse wave velocity, and flow mediated dilation. *Cardiovasc Ultrasound.* **12**:34.
45. Vlachopoulos C, Aznaouridis K, Stefanadis C. (2010) Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. *J Am Coll Cardiol.* **55**(13):1318-27.
46. Hirota T, Ohki K, Kawagishi R, *et al.* (2007) Casein hydrolysate containing the antihypertensive tripeptides Val-Pro-Pro and Ile-Pro-Pro improves vascular endothelial function independent of blood pressure-lowering effects: contribution of the inhibitory action of angiotensin-converting enzyme. *Hypertens Res.* **30**(6):489-96.
47. Jauhiainen T, Ronnback M, Vapaatalo H, *et al.* (2010) Long-term intervention with *Lactobacillus helveticus* fermented milk reduces augmentation index in hypertensive subjects. *Eur J Clin Nutr.* **64**(4):424-31.

48. Turpeinen AM, Kumpu M, Rönneback M, *et al.* (2009) Antihypertensive and cholesterol-lowering effects of a spread containing bioactive peptides IPP and VPP and plant sterols. *Journal of Functional Foods*. **1**(3):260-5.
49. Yoshizawa M, Maeda S, Miyaki A, *et al.* (2009) Additive beneficial effects of lactotripeptides and aerobic exercise on arterial compliance in postmenopausal women. *Am J Physiol Heart Circ Physiol*. **297**(5):H1899-903.
50. Yoshizawa M, Maeda S, Miyaki A, *et al.* (2010) Additive beneficial effects of lactotripeptides intake with regular exercise on endothelium-dependent dilatation in postmenopausal women. *Am J Hypertens*. **23**(4):368-72.
51. Jauhiainen T, Rönneback M, Vapaatalo H, *et al.* (2007) Lactobacillus helveticus fermented milk reduces arterial stiffness in hypertensive subjects. *Int Dairy J*. **17**(10):1209-11.
52. Cicero AF, Rosticci M, Gerocarni B, *et al.* (2011) Lactotripeptides effect on office and 24-h ambulatory blood pressure, blood pressure stress response, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first-degree hypertension: a randomized double-blind clinical trial. *Hypertens Res*. **34**(9):1035-40.
53. Nakamura T, Mizutani J, Ohki K, *et al.* (2011) Casein hydrolysate containing Val-Pro-Pro and Ile-Pro-Pro improves central blood pressure and arterial stiffness in hypertensive subjects: a randomized, double-blind, placebo-controlled trial. *Atherosclerosis*. **219**(1):298-303.
54. Turpeinen AM, Ehlers PI, Kivimäki AS, *et al.* (2011) Ile-Pro-Pro and Val-Pro-Pro tripeptide-containing milk product has acute blood pressure lowering effects in mildly hypertensive subjects. *Clin Exp Hypertens*. **33**(6):388-96.
55. Ballard KD, Kupchak BR, Volk BM, *et al.* (2013) Acute effects of ingestion of a novel whey-derived extract on vascular endothelial function in overweight, middle-aged men and women. *Br J Nutr*. **109**(5):882-93.
56. Ballard KD, Bruno RS, Seip RL, *et al.* (2009) Acute ingestion of a novel whey-derived peptide improves vascular endothelial responses in healthy individuals: a randomized, placebo controlled trial. *Nutr J*. **8**:34.
57. Mariotti F, Valette M, Lopez C, *et al.* (2015) Casein Compared with Whey Proteins Affects the Organization of Dietary Fat during Digestion and Attenuates the Postprandial Triglyceride Response to a Mixed High-Fat Meal in Healthy, Overweight Men. *J Nutr*. **145**(12):2657-64.

58. Franklin SS. (2005) Arterial stiffness and hypertension: a two-way street? *Hypertension*. **45**(3):349-51.
59. Dernellis J, Panaretou M. (2005) Aortic stiffness is an independent predictor of progression to hypertension in nonhypertensive subjects. *Hypertension*. **45**(3):426-31.
60. Sesso HD, Buring JE, Rifai N, *et al.* (2003) C-reactive protein and the risk of developing hypertension. *Jama*. **290**(22):2945-51.
61. Tsai SS, Lin YS, Lin CP, *et al.* (2015) Metabolic Syndrome-Associated Risk Factors and High-Sensitivity C-Reactive Protein Independently Predict Arterial stiffness in 9903 Subjects With and Without Chronic Kidney Disease. *Medicine* (Baltimore). **94**(36):e1419.
62. Henry RM, Kostense PJ, Spijkerman AM, *et al.* (2003) Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study. *Circulation*. **107**(16):2089-95.
63. Singhal A, Farooqi IS, Cole TJ, *et al.* (2002) Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? *Circulation*. **106**(15):1919-24.
64. Baron AD. (1994) Hemodynamic actions of insulin. *Am J Physiol*. **267**(2 Pt 1):E187-202.
65. Rosen OM. (1987) After insulin binds. *Science*. **237**(4821):1452-8.
66. Moore RD. (1983) Effects of insulin upon ion transport. *Biochim Biophys Acta*. **737**(1):1-49.
67. Anderson EA, Hoffman RP, Balon TW, *et al.* (1991) Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. *J Clin Invest*. **87**(6):2246-52.
68. Giugliano D, Marfella R, Verrazzo G, *et al.* (1997) The vascular effects of L-Arginine in humans. The role of endogenous insulin. *J Clin Invest*. **99**(3):433-8.
69. Gates PE, Boucher ML, Silver AE, *et al.* (2007) Impaired flow-mediated dilation with age is not explained by L-arginine bioavailability or endothelial asymmetric dimethylarginine protein expression. *J Appl Physiol* **102**(1):63-71.
70. Floyd JC, Jr., Fajans SS, Conn JW, *et al.* (1966) Insulin secretion in response to protein ingestion. *J Clin Invest*. **45**(9):1479-86.
71. Schmid R, Schusdziarra V, Schulte-Frohlinde E, *et al.* (1989) Role of amino acids in stimulation of postprandial insulin, glucagon, and pancreatic polypeptide in humans. *Pancreas*. **4**(3):305-14.

72. Schmid R, Schulte-Frohlinde E, Schusdziarra V, *et al.* (1992) Contribution of postprandial amino acid levels to stimulation of insulin, glucagon, and pancreatic polypeptide in humans. *Pancreas*. **7**(6):698-704.
73. Nilsson M, Stenberg M, Frid AH, *et al.* (2004) Glycemia and insulinemia in healthy subjects after lactose-equivalent meals of milk and other food proteins: the role of plasma amino acids and incretins. *Am J Clin Nutr*. **80**(5):1246-53.
74. Calbet JA, MacLean DA. (2002) Plasma glucagon and insulin responses depend on the rate of appearance of amino acids after ingestion of different protein solutions in humans. *J Nutr*. **132**(8):2174-82.
75. Calbet JA, Holst JJ. (2004) Gastric emptying, gastric secretion and enterogastrone response after administration of milk proteins or their peptide hydrolysates in humans. *Eur J Nutr*. **43**(3):127-39.
76. van Loon LJ, Saris WH, Verhagen H, *et al.* (200) Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate. *Am J Clin Nutr*. **72**(1):96-105.
77. Yang J, Chi Y, Burkhardt BR, *et al.* (2010) Leucine metabolism in regulation of insulin secretion from pancreatic beta cells. *Nutr Rev*. **68**(5):270-9.
78. Melnik BC. (2012) Leucine signaling in the pathogenesis of type 2 diabetes and obesity. *World J Diabetes*. **3**(3):38-53.
79. Yabe D, Seino Y. (2011) Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and beta cell preservation. *Prog Biophys Mol Biol*. **107**(2):248-56.
80. Jakubowicz D, Froy O. (2013) Biochemical and metabolic mechanisms by which dietary whey protein may combat obesity and Type 2 diabetes. *J Nutr Biochem*. **24**(1):1-5.
81. Poudyal H. (2015) Mechanisms for the Cardiovascular Effects of Glucagon-Like Peptide-1. *Acta Physiol (Oxf)*. doi: 10.1111/apha.12604. [Epub ahead of print]
82. Hall WL, Millward DJ, Long SJ, *et al.* (2003) Casein and whey exert different effects on plasma amino acid profiles, gastrointestinal hormone secretion and appetite. *Br J Nutr*. **89**(2):239-48.
83. Veldhorst MA, Nieuwenhuizen AG, Hochstenbach-Waelen A, *et al.* (2009) Dose-dependent satiating effect of whey relative to casein or soy. *Physiol Behav*. **96**(4-5):675-82.

84. Fan H, Yan S, Stehling S, *et al.* (2003) Dipeptidyl peptidase IV/CD26 in T cell activation, cytokine secretion and immunoglobulin production. *Adv Exp Med Biol.* **524**:165-74.
85. Lacroix IME, Li-Chan ECY. (2012) Evaluation of the potential of dietary proteins as precursors of dipeptidyl peptidase (DPP)-IV inhibitors by an in silico approach. *J Funct Foods.* **4**(2):403-22.
86. Patil P, Mandal S, Tomar SK, *et al.* (2015) Food protein-derived bioactive peptides in management of type 2 diabetes. *Eur J Nutr.* **54**(6):863-80.
87. Slama G, Elgrably F, Sola A, *et al.* (2006) Postprandial glycaemia: a plea for the frequent use of delta postprandial glycaemia in the treatment of diabetic patients. *Diabetes Metab.* **32**(2):187-92.
88. Lacroix IM, Li-Chan EC. (2013) Inhibition of dipeptidyl peptidase (DPP)-IV and alpha-glucosidase activities by pepsin-treated whey proteins. *J Agric Food Chem.* **61**(31):7500-6.
89. Konrad B, Anna D, Marek S, *et al.* (2014) The Evaluation of Dipeptidyl Peptidase (DPP)-IV, alpha-Glucosidase and Angiotensin Converting Enzyme (ACE) Inhibitory Activities of Whey Proteins Hydrolyzed with Serine Protease Isolated from Asian Pumpkin. *Int J Pept Res Ther.* **20**(4):483-91.
90. Petersen BL, Ward LS, Bastian ED, *et al.* (2009) A whey protein supplement decreases post-prandial glycemia. *Nutr J.* **8**:47.
91. Pal S, Ellis V. (2010) The acute effects of four protein meals on insulin, glucose, appetite and energy intake in lean men. *Br J Nutr.* **104**(8):1241-8.
92. Akhavan T, Luhovyy BL, Panahi S, *et al.* (2014) Mechanism of action of pre-meal consumption of whey protein on glycemic control in young adults. *J Nutr Biochem.* **25**(1):36-43.
93. Akhavan T, Luhovyy BL, Brown PH, *et al.* (2010) Effect of premeal consumption of whey protein and its hydrolysate on food intake and postmeal glycemia and insulin responses in young adults. *Am J Clin Nutr.* **91**(4):966-75.
94. Acheson KJ, Blondel-Lubrano A, Oguey-Araymon S, *et al.* (2011) Protein choices targeting thermogenesis and metabolism. *Am J Clin Nutr.* **93**(3):525-34.
95. Morifuji M, Ishizaka M, Baba S, *et al.* (2010) Comparison of different sources and degrees of hydrolysis of dietary protein: effect on plasma amino acids, dipeptides, and insulin responses in human subjects. *J Agric Food Chem.* **58**(15):8788-97.

96. Pal S, Ellis V, Dhaliwal S. (2010) Effects of whey protein isolate on body composition, lipids, insulin and glucose in overweight and obese individuals. *Br J Nutr.* **104**(5):716-23.
97. Nilsson M, Holst JJ, Bjorck IM. (2007) Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks. *Am J Clin Nutr.* **85**(4):996-1004.
98. Holmer-Jensen J, Mortensen LS, Astrup A, *et al.* (2013) Acute differential effects of dietary protein quality on postprandial lipemia in obese non-diabetic subjects. *Nutr Res.* **33**(1):34-40.
99. Holmer-Jensen J, Hartvigsen ML, Mortensen LS, *et al.* (2012) Acute differential effects of milk-derived dietary proteins on postprandial lipaemia in obese non-diabetic subjects. *Eur J Clin Nutr.* **66**(1):32-8.
100. Frid AH, Nilsson M, Holst JJ, *et al.* (2005) Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. *Am J Clin Nutr.* **82**(1):69-75.
101. Ma J, Stevens JE, Cukier K, *et al.* (2009) Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate meal in diet-controlled type 2 diabetes. *Diabetes Care.* **32**(9):1600-2.
102. Ma J, Jesudason DR, Stevens JE, *et al.* (2015) Sustained effects of a protein 'preload' on glycaemia and gastric emptying over 4 weeks in patients with type 2 diabetes: A randomized clinical trial. *Diabetes Res Clin Pract.* **108**(2):e31-4.
103. Mortensen LS, Hartvigsen ML, Brader LJ, *et al.* (2009) Differential effects of protein quality on postprandial lipemia in response to a fat-rich meal in type 2 diabetes: comparison of whey, casein, gluten, and cod protein. *Am J Clin Nutr.* **90**(1):41-8.
104. Mortensen LS, Holmer-Jensen J, Hartvigsen ML, *et al.* (2012) Effects of different fractions of whey protein on postprandial lipid and hormone responses in type 2 diabetes. *Eur J Clin Nutr.* **66**(7):799-805.
105. Jonker JT, Wijngaarden MA, Kloek J, *et al.* (2011) Effects of low doses of casein hydrolysate on post-challenge glucose and insulin levels. *Eur J Intern Med.* **22**(3):245-8.
106. Geerts BF, van Dongen MG, Flameling B, *et al.* (2011) Hydrolyzed casein decreases postprandial glucose concentrations in T2DM patients irrespective of leucine content. *J Diet Suppl.* **8**(3):280-92.

- 783 107. McGregor RA, Poppitt SD. (2013) Milk protein for improved metabolic health: a
784 review of the evidence. *Nutr Metab (Lond)*. **10**(1):46.
- 785 108. Gouni-Berthold I, Schulte DM, Krone W, *et al.* (2012) The whey fermentation product
786 malleable protein matrix decreases TAG concentrations in patients with the metabolic
787 syndrome: a randomised placebo-controlled trial. *Br J Nutr*. **107**(11):1694-706.
- 788 109. Teno S, Uto Y, Nagashima H, *et al.* (200) Association of postprandial
789 hypertriglyceridemia and carotid intima-media thickness in patients with type 2
790 diabetes. *Diabetes Care*. **23**(9):1401-6.
- 791 110. Vigna GB, Delli Gatti C, Fellin R. (2004) Endothelial function and postprandial
792 lipemia. *Nutr Metab Cardiovasc Dis*. **14**(3):121-7.
- 793 111. Thomsen C, Storm H, Holst JJ, *et al.* (2003) Differential effects of saturated and
794 monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in
795 patients with type 2 diabetes. *Am J Clin Nutr*. **77**(3):605-11.
- 796 112. Thomsen C, Rasmussen O, Lousen T, *et al.* (1999) Differential effects of saturated and
797 monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy
798 subjects. *Am J Clin Nutr*. **69**(6):1135-43.
- 799 113. Cohen JC, Schall R. (1988) Reassessing the effects of simple carbohydrates on the
800 serum triglyceride responses to fat meals. *Am J Clin Nutr*. **48**(4):1031-4.
- 801 114. Lairon D, Play B, Jourdheuil-Rahmani D. (2007) Digestible and indigestible
802 carbohydrates: interactions with postprandial lipid metabolism. *J Nutr Biochem*.
803 **18**(4):217-27.
- 804 115. Brader L, Holm L, Mortensen L, *et al.* (2010) Acute effects of casein on postprandial
805 lipemia and incretin responses in type 2 diabetic subjects. *Nutr Metab Cardiovasc Dis*.
806 **20**(2):101-9.
- 807 116. Olefsky JM, Crapo P, Reaven GM. (1976) Postprandial plasma triglyceride and
808 cholesterol responses to a low-fat meal. *Am J Clin Nutr*. **29**(5):535-9.
- 809 117. Roche HM, Zampelas A, Knapper JM, *et al.* (1998) Effect of long-term olive oil
810 dietary intervention on postprandial triacylglycerol and factor VII metabolism. *Am J*
811 *Clin Nutr*. **68**(3):552-60.
- 812 118. Claessens M, van Baak MA, Monsheimer S, *et al.* (2009) The effect of a low-fat, high-
813 protein or high-carbohydrate ad libitum diet on weight loss maintenance and metabolic
814 risk factors. *Int J Obes (Lond)*. **33**(3):296-304.

- 815 119. Weisse K, Brandsch C, Zernsdorf B, *et al.* (2010) Lupin protein compared to casein
816 lowers the LDL cholesterol:HDL cholesterol-ratio of hypercholesterolemic adults. *Eur*
817 *J Nutr.* 49(2):65-71.
- 818 120. Chen Q, Reimer RA. (2009) Dairy protein and leucine alter GLP-1 release and mRNA
819 of genes involved in intestinal lipid metabolism in vitro. *Nutrition.* **25**(3):340-9.
- 820 121. Lillefosse HH, Clausen MR, Yde CC, *et al.* (2014) Urinary loss of tricarboxylic acid
821 cycle intermediates as revealed by metabolomics studies: an underlying mechanism to
822 reduce lipid accretion by whey protein ingestion? *J Proteome Res.* **13**(5):2560-70.
- 823 122. Zheng H, Yde CC, Clausen MR, *et al.* (2015) Metabolomics investigation to shed light
824 on cheese as a possible piece in the French paradox puzzle. *J Agric Food Chem.*
825 **63**(10):2830-9.
- 826 123. Tremaroli V, Backhed F. (2012) Functional interactions between the gut microbiota
827 and host metabolism. *Nature.* **489**(7415):242-9.
- 828 124. Hamad EM, Taha SH, Abou Dawood AG, *et al.* (2011) Protective effect of whey
829 proteins against nonalcoholic fatty liver in rats. *Lipids Health Dis.* **10**:57.
- 830 125. Lorenzen J, Frederiksen R, Hoppe C, *et al.* (2012) The effect of milk proteins on
831 appetite regulation and diet-induced thermogenesis. *Eur J Clin Nutr.* **66**(5):622-7.
- 832 126. Lorenzen JK, Astrup A. (2011) Dairy calcium intake modifies responsiveness of fat
833 metabolism and blood lipids to a high-fat diet. *Br J Nutr.* **105**(12):1823-31.
- 834 127. Gacs G, Barltrop D. (1977) Significance of Ca-soap formation for calcium absorption
835 in the rat. *Gut.* **18**(1):64-8.
- 836 128. Govers MJ, Termont DS, Van Aken GA, *et al.* (1994) Characterization of the
837 adsorption of conjugated and unconjugated bile acids to insoluble, amorphous calcium
838 phosphate. *J Lipid Res.* **35**(5):741-8.
- 839 129. Biro FM, Wien M. (2010) Childhood obesity and adult morbidities. *Am J Clin Nutr.*
840 **91**(5):1499s-505s.
- 841 130. Conen D, Rexrode KM, Creager MA, *et al.* (2009) Metabolic syndrome,
842 inflammation, and risk of symptomatic peripheral artery disease in women: a
843 prospective study. *Circulation.* **120**(12):1041-7.
- 844 131. Libby P, Ridker PM, Hansson GK. (2009) Inflammation in atherosclerosis: from
845 pathophysiology to practice. *J Am Coll Cardiol.* **54**(23):2129-38.
- 846 132. Galland L. (2010) Diet and inflammation. *Nutr Clin Pract.* **25**(6):634-40.

- 847 133. Zhou LM, Xu JY, Rao CP, *et al.* (2015) Effect of whey supplementation on circulating
848 C-reactive protein: a meta-analysis of randomized controlled trials. *Nutrients*.
849 **7**(2):1131-43.
- 850 134. Sugawara K, Takahashi H, Kashiwagura T, *et al.* (2012) Effect of anti-inflammatory
851 supplementation with whey peptide and exercise therapy in patients with COPD.
852 *Respir Med.* **106**(11):1526-34.
- 853 135. Bharadwaj S, Naidu TA, Betageri GV, *et al.* (2010) Inflammatory responses improve
854 with milk ribonuclease-enriched lactoferrin supplementation in postmenopausal
855 women. *Inflamm Res.* **59**(11):971-8.
- 856 136. Kerasioti E, Stagos D, Jamurtas A, *et al.* (2013) Anti-inflammatory effects of a special
857 carbohydrate-whey protein cake after exhaustive cycling in humans. *Food Chem*
858 *Toxicol.* **61**:42-6.
- 859 137. Holmer-Jensen J, Karhu T, Mortensen LS, *et al.* (2011) Differential effects of dietary
860 protein sources on postprandial low-grade inflammation after a single high fat meal in
861 obese non-diabetic subjects. *Nutr J.* **10**:115.
- 862 138. Sun X, Zemel MB. (2007) Calcium and 1,25-dihydroxyvitamin D3 regulation of
863 adipokine expression. *Obesity* (Silver Spring). **15**(2):340-8.
- 864 139. Kalupahana NS, Moustaid-Moussa N. (2012) The renin-angiotensin system: a link
865 between obesity, inflammation and insulin resistance. *Obes Rev.* **13**(2):136-49.

Table 1. Impacts of milk proteins on blood pressure.

Reference	Subjects (n)	Study design and duration	Treatment (g)	Comparison	Treatment effect
LONG-TERM					
Petyaev <i>et al.</i> ⁽³⁴⁾	Prehypertensive (40)	Pilot, 4 weeks	Whey protein isolate (70 mg) embedded into lycopene micelles (7 mg)	Whey protein isolate, lycopene and placebo	↓BP
Arnberg <i>et al.</i> ⁽³⁵⁾	Overweight adolescents (193)	12 weeks	Casein (35g/L), whey protein (35g/L) and skimmed milk (1 litre)	Water, pretest control group	↓bBP and cDBP in casein group, ↑cDBP, bSBP and cSBP in whey group
Figueroa <i>et al.</i> ⁽³⁶⁾	Obese women (33)	4 weeks	Casein, whey protein	Carbohydrate	↓bSBP and aSBP in casein and whey groups
SHORT-TERM					
Teunissen-Beekman <i>et al.</i> ⁽⁴⁰⁾	Overweight or obese (48)	240 mins	Milk protein, pea protein, egg-white protein	Maltodextrin	↓BP milk and pea protein groups compared to egg-white protein group

↑, Increase; ↓, Decrease; BP, blood pressure; bBP, brachial blood pressure; cBP, central blood pressure; DBP; diastolic blood pressure; SBP, systolic blood pressure

Table 2. Impacts of milk proteins on vascular function

Reference	Subjects (n)	Study design and duration	Treatment (g)	Comparison	Treatment effect
LONG-TERM					
Petyaev <i>et al.</i> ⁽³⁴⁾	Prehypertensive (40)	Pilot, 4 weeks	Whey protein isolate (70 mg) embedded into lycopene micelles (7 mg)	Whey protein isolate, lycopene and placebo	↑FMD
Arnberg <i>et al.</i> ⁽³⁵⁾	Overweight adolescents (193)	12 weeks	Casein (35g/L), whey protein (35g/L) and skimmed milk (1 litre)	Water, pretest control group	↔
SHORT-TERM					
Mariott ⁽⁵⁷⁾	Overweight men (10)	360 mins	Casein	Whey protein isolate, α-lactalbumin-enriched whey protein	↔
FMD, flow-mediated dilation, ↑, Increase; ↔, no effect					

Table 3. Impacts of milk proteins on glycaemic control.

Reference	Subjects (n)	Study design and duration	Treatment (g)	Comparison	Treatment effect
SHORT-TERM					
Nilsson <i>et al.</i> ⁽⁷³⁾	Healthy (12)	120 mins	WP (18.2 g)	White-wheat bread, milk, cod, cheese, gluten-low, gluten-high	↑Insulin response, ↑GIP, ↔GLP-1
Calbet <i>et al.</i> ⁽⁷⁵⁾	Healthy (6)	120 mins	HC (36 g)	Intact casein	↑GIP
Hall <i>et al.</i> ⁽⁸²⁾	Healthy (9)	180 mins	WP (48 g)	Casein	↑GLP-1
Veldhorst <i>et al.</i> ⁽⁸³⁾	Healthy (25)	180 mins	WP (10 and 25%)	Casein, soy	↑GLP-1
Petersen <i>et al.</i> ⁽⁹⁰⁾	Healthy (10)	120 mins	WP (20 g)	Glucose	↓Glucose response
Pal and Ellis ⁽⁹¹⁾	Healthy men (22)	240 mins	WP (50.8 g)	Turkey, egg, tuna	↓Glucose response, ↑Insulin response
Akhavan <i>et al.</i> ⁽⁹²⁾	Healthy (10)	230 mins	WP as pre-meal (10-20 g)	Glucose, water	↓Glucose response, ↑GLP-1, ↑GIP
Akhavan <i>et al.</i> ⁽⁹³⁾	Healthy (16/21)	170 mins	WP as pre-meal (10-40 g)	Water	↓Glucose response
Acheson <i>et al.</i> ⁽⁹⁴⁾	Healthy (23)	330 mins	WPI (50 % of diet)	Casein, soy, glucose	↑Insulin response
Morifuji <i>et al.</i> ⁽⁹⁵⁾	Healthy (10)	120 mins	WPH (86,9%)	WP, soy, soy hydrolysate	↑Insulin response
Nilsson <i>et al.</i> ⁽⁹⁷⁾	Healthy (12)	120 mins	WP (18 g)	Glucose, amino acids	↔GLP-1
Holmer-Jensen <i>et al.</i> ⁽⁹⁸⁾	Obese (11)	480 mins	WPI + fat-rich meal (45 g)	Casein and gluten	↓GIP
Holmer-Jensen <i>et al.</i> ⁽⁹⁹⁾	Obese (12)	480 mins	WPI + fat-rich meal (45 g)	WP specific fractions	↔GLP-1
Frid <i>et al.</i> ⁽¹⁰⁰⁾	T2D (14)	240 mins	WP (27.6 g)	Ham (96 g) + lactose (5.3 g)	↓Glucose response, ↑Insulin response
Ma <i>et al.</i> ⁽¹⁰¹⁾	T2D (8)	300 mins	WP as pre-meal (55 g)	WP in main meal	↑Insulin and incretin response
Ma <i>et al.</i> ⁽¹⁰²⁾	T2D (7)	240 mins	WPI (25 g)	'diet' drink	↓Glucose response
Mortensen <i>et al.</i> ⁽¹⁰³⁾	T2D (12)	480 mins	WPI + fat-rich meal (45 g)	Casein, gluten, cod	↔GLP-1, ↓GIP
Mortensen <i>et al.</i> ⁽¹⁰⁴⁾	T2D (12)	480 mins	WPI + fat-rich meal (45 g)	WP specific fractions	↔GLP-1
Jonker <i>et al.</i> ⁽¹⁰⁵⁾	T2D (13)	250 mins	CH (12 g)	CH (0 g)	↑Insulin response

Geerts <i>et al.</i> ⁽¹⁰⁶⁾	T2D (36)	240 mins	CH (12 g)	Intact casein	↓Glucose response
LONG-TERM					
Pal <i>et al.</i> ⁽⁹⁶⁾	Overweight and obese (70)	12 weeks	WPI (2x27 g/d)	Glucose	↑Fasting insulin + HOMA-IR
Ma <i>et al.</i> ⁽¹⁰²⁾	T2D (7)	4 weeks	WPI (25 g)	'diet' drink	↓Glucose response
Gouni-Berthold <i>et al.</i> ⁽¹⁰⁸⁾	MS (180)	12 weeks	Whey MPM (15.3g)	Placebo	↓Glucose response

↑, Increase; ↓, Decrease; ↔, no effect; CH, casein hydrolysate; D, day; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide 1; HC, hydrolysed casein; HOMA-IR, homeostasis model assessment of insulin resistance; MS, metabolic syndrome; T2D, type-2 diabetes; Whey MPM, whey malleable protein matrix; WP, whey protein; WPH, whey protein hydrolysate; WPI, whey protein isolate.

Table 4. Impacts of milk proteins on lipid metabolism.

Reference	Subjects (n)	Study design and duration	Treatment (g)	Comparison	Treatment effect
SHORT-TERM					
Brader <i>et al.</i> ⁽¹¹⁵⁾	T2D (11)	480 mins	Casein combined with carbohydrates and a fat-rich meal (45 g)	Control meal, control meal+carbohydrate, control meal+casein	↓TAG concentration in chylomicron-rich fraction
Holmer-Jensen <i>et al.</i> ⁽⁹⁸⁾	Obese (11)	480 mins	WPI + fat-rich meal (45 g)	Cod and gluten	↓TAG response, ↓TAG concentration in chylomicron-rich fraction, ↓FFA
Holmer-Jensen <i>et al.</i> ⁽⁹⁹⁾	Obese (12)	480 mins	WPI + fat-rich meal (45 g)	WP specific fractions	↔TAG response
Mortensen <i>et al.</i> ⁽¹⁰³⁾	T2D (12)	480 mins	WPI + fat-rich meal (45 g)	Casein, gluten, cod	↓TAG response, ↓FFA
Mortensen <i>et al.</i> ⁽¹⁰⁴⁾	T2D (12)	480 mins	WPI + fat-rich meal (45 g)	WP specific fractions	↔TAG response
LONG-TERM					
Pal <i>et al.</i> ⁽⁹⁶⁾	Overweight and obese (70)	12 weeks	WPI (2x27 g/d)	Glucose	↓Fasting TAG, ↓TC, ↓LDL-c
Weisse <i>et al.</i> ⁽¹¹⁹⁾	Hyper-cholesterolemic (43)	6 weeks	Casein (35 g/d)	Baseline	↓TC
Claessens <i>et al.</i> ⁽¹¹⁸⁾	Obese (48)	12 weeks	WP (2x25 g/d)	Casein	↔fasting lipids
Petyaev <i>et al.</i> ⁽³⁴⁾	Prehypertensive (40)	Pilot, 4 weeks	Whey protein isolate (70 mg) embedded into lycopene micelles (7 mg)	Whey protein isolate, lycopene and placebo	↓TC, ↓TAG, ↓LDL-c, ↑HDL
Gouni-Berthold <i>et al.</i> ⁽¹⁰⁸⁾	MS (180)	12 weeks	Whey MPM (15.3g)	Placebo	↓TAG

↑, Increase; ↓, Decrease; ↔, no effect; CH, casein hydrolysate; D, day; FFA, free fatty acids; HC, hydrolysed casein; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; MS, metabolic syndrome; T2D, type-2 diabetes; TAG, triacylglycerol; TC, total cholesterol; Whey MPM, whey malleable protein matrix; WP, whey protein; WPH, whey protein hydrolysate; WPI, whey protein isolate.

Table 5. Impacts of milk proteins on inflammation and oxidative stress.

Reference	Subjects (n)	Study design and duration	Treatment (g)	Comparison	Treatment effect
LONG-TERM					
Sugawara <i>et al.</i> ⁽¹³⁴⁾	COPD (36)	12 weeks	WP (20 g)	0 g WP	↓CRP, ↓IL-6, ↓IL-8, ↓TNF-α
Bharadwaj <i>et al.</i> ⁽¹³⁵⁾	Post-menopausal women (38)	24 weeks	Ribonuclease-enriched lactoferrin (2 × 125 mg/d)	Placebo	↓IL-6, ↓TNF-α
Arnberg <i>et al.</i> ⁽³⁵⁾	Overweight adolescents (193)	12 weeks	Casein (35g/L), whey protein (35g/L)	Water, pretest control group	↑CRP
Pal and Ellis ⁽³³⁾	Overweight (70)	12 weeks	WPI (54 g), Casein (54 g)	Glucose	↔CRP, ↔IL-6, ↔TNF-α
Hirota <i>et al.</i> ⁽⁴⁶⁾	Mild hypertensives (25)	1 week	VPP (3.42 mg), IPP (3.87 mg)	Baseline	↔CRP, ↓TNF-α
SHORT-TERM					
Pal and Ellis ⁽³²⁾	Overweight postmenopausal women (20)	480 mins	WPI (45 g), Casein (45 g)	Glucose	↔CRP, ↔IL-6, ↔TNF-α
Ballard <i>et al.</i> ⁽⁵⁶⁾	Healthy (20)	120 mins	Whey-derived peptide (NOP-47, 5 g)	Placebo	↔CRP, ↔IL-6, ↔IL-8, ↔TNF-α
Kerasioti <i>et al.</i> ⁽¹³⁶⁾	Healthy men (9)	48 h	WP (0.26 g protein/kg BW/h)	Placebo	↓CRP, ↓IL-6, ↑IL-10
Holmer-Jensen <i>et al.</i> ⁽¹³⁷⁾	Obese (11)	240 mins	WP + high-fat meal	Casein, cod and gluten + high-fat meal	↓CCL5/RANTES, ↑MCP-1

↑, Increase; ↓, Decrease; ↔, no effect; BW, body weight; CCL, CC chemokine ligand-5; CH, casein hydrolysate; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; D, day; IL, interleukin; IPP, Isoleucine-Proline-Proline; MCP-1, monocyte chemotactic protein-1; TNF, tumor necrosis factor; VPP, Valine-Proline-Proline; Whey MPM, whey malleable protein matrix; WP, whey protein; WPH, whey protein hydrolysate; WPI, whey protein isolate.